Adverts

Open Access Articles- Top Results for LGD-4033

LGD-4033

</th></tr></th></tr>
LGD-4033
240px
Systematic (IUPAC) name
4-((R)-2-((R)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl)-2-trifluoroMethyl)benzonitrile
Clinical data
  • Investigational new drug
Oral
Pharmacokinetic data
Half-life 24-36 hours [1]
Identifiers
1165910-22-4
None
PubChem CID 44137686
Chemical data
Formula C14H12F6N2O

LGD-4033 is an investigational selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wasting and osteoporosis, currently under development by Ligand Pharmaceuticals.[2]

References

  1. ^ Basaria S, Collins L, Dillon EL, Orwoll K, Storer TW et al. (Jan 2013). "The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men.". J Gerontol A Biol Sci Med Sci 68: 87–95. PMID 22459616. doi:10.1093/gerona/gls078. 
  2. ^ "Ligand Presents New Preclinical Data on its Lead SARM Molecule LGD-4033 at the Gerontological Society of America Annual Meeting" (Press release). San Diego: Ligand Pharmaceuticals. November 20, 2009. Retrieved November 23, 2014.